Overview of Dr. Ortiz
Dr. Michael Ortiz is a pediatric hematologist/oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from University of Florida College of Medicine and has been in practice 7 years. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center who specialize in Pediatric Hematology & Oncology. He has more than 40 publications and over 500 citings.
Office
1275 York Avenue
New York, NY 10065
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2014 - 2017
Children's National HospitalChief Residency, Pediatrics, 2013 - 2014- Children's National HospitalResidency, Pediatrics, 2010 - 2013
University of Florida College of MedicineClass of 2010, M.D.
Certifications & Licensure
FL State Medical License 2023 - Present
NJ State Medical License 2024 - 2025
NY State Medical License 2014 - 2025
DC State Medical License 2010 - 2014- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors Start of enrollment: 2020 Dec 10
Roles: Contact, Principal Investigator
- A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment Start of enrollment: 2021 Jun 09
Roles: Principal Investigator, Contact
- A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors Start of enrollment: 2023 Aug 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 4 citationsPaediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaborat...Andrew D J Pearson, Sara Federico, Susanne A Gatz, Michael Ortiz, Giovanni Lesa
European Journal of Cancer. 2023-09-01 - 7 citationsBromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.Andrew D. Woods, Noah E. Berlow, Michael V. Ortiz, Filemon S. Dela Cruz, Armaan Siddiquee
Pediatric Blood & Cancer. 2021-10-24 - 3 citationsElimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models.Fabian F Pusch, Heathcliff Dorado García, Robin Xu, Dennis Gürgen, Yi Bei
Molecular Cancer Therapeutics. 2024-04-02
Grant Support
- NCIMemorial Sloan Kettering Cancer Center2017–2020
External Links
- MSK Kidshttps://www.mskcc.org/cancer-care/doctors/michael-ortiz
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
